Neclife Lifesciences receives Korean FDA for 'Cefuroxime Axetil'
New Delhi | Wednesday, Sep 8 2010 IST
Pharmaceutical firm NecLife Lifesciences today announced that it has received Korean food and drug administration's (K-FDA) approval for Cefuroxime Axetil (Amorphous).
''We are optimistic about the new market as we believe South Korea is well placed to register substantial growth in coming years. This approval enables us to further augment our position in the cephalosporin market in three major molecules,'' Nectar Lifesciences Chief Executive Officer (CEO) and Director Dinesh Dua said.
The company expects business potential for the approved molecule 'Cefuroxime Axetil (Amorphous)' to the tune of 10 million dollars, he said.
-- (UNI) -- 08DC6.xml
Watch News Videos